Fresenius SE & Co KGaA (FRA:FRE) Earns “Buy” Rating from Citigroup

Fresenius SE & Co KGaA (FRA:FRE)‘s stock had its “buy” rating reaffirmed by equities researchers at Citigroup in a research note issued on Friday, December 1st.

A number of other brokerages have also recently issued reports on FRE. Goldman Sachs Group set a €74.50 ($88.69) target price on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Friday, December 1st. Kepler Capital Markets set a €63.00 ($75.00) price target on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research report on Tuesday, November 28th. Independent Research set a €80.00 ($95.24) price target on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research report on Thursday, November 23rd. HSBC set a €70.00 ($83.33) target price on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Wednesday, November 22nd. Finally, Berenberg Bank set a €89.10 ($106.07) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Seven equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of €79.48 ($94.61).

Fresenius SE & Co KGaA (FRA:FRE) opened at €66.53 ($79.20) on Friday. Fresenius SE & Co KGaA has a 1 year low of €60.16 ($71.62) and a 1 year high of €80.00 ($95.24).

TRADEMARK VIOLATION WARNING: “Fresenius SE & Co KGaA (FRA:FRE) Earns “Buy” Rating from Citigroup” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/14/fresenius-se-co-kgaa-fre-earns-buy-rating-from-citigroup.html.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply